Details:
The partnership will leverage Elixirgen's proprietary ZSCAN4 therapy platform to advance treatments of aging-associated diseases. Elixirgen Therapeutics is currently performing a Phase I/II clinical trial using its ZSCAN4 therapy platform in disorders with bone marrow failure.
Lead Product(s): ZSCAN4-based Therapeutic
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Elixirgen Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 07, 2022